A clinical trial is a way of testing possible new treatment regimes which could prove more effective or cause fewer side effects than those being used.
Traditional clinical trials test only one drug or different aspect of a treatment at a time. As a result, it can take several years to produce results, wheter positive or negative. This is not helpful for patients with a high-grade, aggressive tumour.
In an adaptive clinical trial, researchers can add in new drugs or combinations of therapies as the trial goes along, in response to the improved or worsening condition of the patients involved. The effect is to speed up results, with the aim of making more effective and kinder treatments available more quickly.
If you have been diagnosed with an aggressive brain tumour and given no hope of a cure, it is very difficult to understand why you shouldn't be allowed to try new treatments or combinations of treatments that might extend your life.
This lack of flexibility in clinical trials has been one factor in historically slow progress towards more effective treatments for high-grade brain tumours.
These tumours progress very quickly – there is simply not enough time for a patient to take part in different trials, each of which tests a single potential treatment.
The adaptive clinical trials we are currently funding are:
We recently announced funding for a brand new adaptive clinical trial to improve treatments for those diagnosed with a glioma, the most common type of brain tumour. The flexible design of the trial will give more patients in the UK the opportunity to be part of a clinical trial and access the newest treatments – something that Baroness Tessa Jowell felt strongly about.
We're currently reviewing applications from researchers who have applied for this funding following input from our patient-led Research Involvement Network, and look forward to the launch of a new trial that will speed up the development of better glioma treatments.
BIOMEDE is the UK's first adaptive trial for children with a brain tumour
Led by Dr Darren Hargrave and funded by The Brain Tumour Charity, the international trial will test improved treatments for children diagnosed with DIPG – one of the most deadly and aggressive childhood brain cancers. As an adaptive trial, BIOMEDE is designed in a smart and flexible way that allows clinicians to eliminate failing drugs and introduce new drugs without restarting the trial. This means we can get new and better treatments to children who desperately need them, much more quickly, saving valuable time and cost.
WINDOW will test many drug combinations to target different cells within each individual patient's tumour as well as looking at differences in tumour between patients.
By experimentally testing up to 100 combinations of drugs which already have clinical approval, WINDOW aims to accelerate the development of new treatments for glioblastoma. The creation of such an integrated approach for effective treatment is expected to accelerate the development of new combination therapies and to seed development of new molecular approaches to treat glioblastoma.